Purius Overview

  • Founded
  • 2016
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private

Purius General Information


Developer of a novel pharmaceutical technological process designed to exploit opportunities within the pharmaceutical sector. The company's drug defining process eliminates the use of resin, filters and other consumables, enabling the pharmaceutical and biotechnology industries to eliminate a considerable percentage of downstream processing costs

Contact Information

Formerly Known As
Affinity & Beyond Technologies Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 20-22 Wenlock Road
  • London N1 7GU
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Purius Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 00000 Completed Startup
1. Seed Round 16-Jan-2017 00000 00000 00000 Completed Startup
To view Purius’s complete valuation and funding history, request access »

Purius Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.00
To view Purius’s complete cap table history, request access »

Purius Executive Team (4)

Name Title Board Seat Contact Info
Michael Rose Chief Executive Officer & Co-Founder
Subhas Pradhan Ph.D Co-Founder & Chief Technology Officer
Anika Ahmad Co-Founder
Savvas Neophytou Ph.D Co-Founder and Investing Partner
To view Purius’s complete executive team members history, request access »